Raymond Schinazi Biography and Net Worth

Major Shareholder of Cocrystal Pharma

Mr. Raymond Schinazi is the Major Shareholder of Cocrystal Pharma.

What is Raymond F. Schinazi's net worth?: The estimated net worth of Raymond F. Schinazi is at least $7.94 million as of May 4th, 2021. Mr. Schinazi owns 7,674,960 shares of Cocrystal Pharma stock worth more than $7,943,584 as of December 4th. This net worth estimate does not reflect any other investments that Mr. Schinazi may own. Learn More about Raymond F. Schinazi's net worth.
How do I contact Raymond F. Schinazi?: The corporate mailing address for Mr. Schinazi and other Cocrystal Pharma executives is 19805 N. CREEK PARKWAY, BOTHELL WA, 98011. Cocrystal Pharma can also be reached via phone at (305) 425-1780 and via email at [email protected]. Learn More on Raymond F. Schinazi's contact information.
Has Raymond F. Schinazi been buying or selling shares of Cocrystal Pharma?: Raymond F. Schinazi has not been actively trading shares of Cocrystal Pharma in the last ninety days. Most recently, Raymond F. Schinazi sold 575,000 shares of the business's stock in a transaction on Tuesday, May 4th. The shares were sold at an average price of $2.95, for a transaction totalling $1,696,250.00. Following the completion of the sale, the insider now directly owns 7,674,960 shares of the company's stock, valued at $22,641,132. Learn More on Raymond F. Schinazi's trading history.
Who are Cocrystal Pharma's active insiders?: Cocrystal Pharma's insider roster includes Richard Pfenniger, Jr. (Director), and Raymond Schinazi (Major Shareholder). Learn More on Cocrystal Pharma's active insiders.
Are insiders buying or selling shares of Cocrystal Pharma?: In the last twelve months, Cocrystal Pharma insiders bought shares 2 times. They purchased a total of 24,000 shares worth more than $22,760.00. The most recent insider tranaction occured on November, 26th when Director Phillip Md Et Al Frost bought 4,000 shares worth more than $3,960.00. Insiders at Cocrystal Pharma own 28.1% of the company. Learn More about insider trades at Cocrystal Pharma.
Information on this page was last updated on 11/26/2025.

Raymond F. Schinazi Insider Trading History at Cocrystal Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/4/2021	Sell	575,000	$2.95	$1,696,250.00	7,674,960
10/25/2019	Buy	16,935	$1.11	$18,797.85
9/1/2016	Buy	4,878,050	$0.41	$2,000,000.50	275,520,853
4/21/2015	Buy	3,464,855	$0.92	$3,187,666.60

Raymond F. Schinazi Buying and Selling Activity at Cocrystal Pharma

Cocrystal Pharma Company Overview

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

Today's Range

Now: $1.04

$1.01

$1.04

50 Day Range

MA: $1.09

$0.90

$1.26

2 Week Range

Now: $1.04

$0.90

$3.26

Volume

48,692 shs

Average Volume

71,717 shs

Market Capitalization

$14.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05